Attention Deficit Hyperactivity Disorder Adhd Pipeline Insight

DelveInsight’s, “Attention Deficit Hyperactivity Disorder – Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Attention Deficit Hyperactivity Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Attention Deficit Hyperactivity Disorder Understanding

Attention Deficit Hyperactivity Disorder: Overview

ADHD is one of the most common neurodevelopmental disorders of childhood. It is usually first diagnosed in childhood and often lasts into adulthood. Children with ADHD may have trouble paying attention, controlling impulsive behaviors (may act without thinking about what the result will be), or be overly active. The symptoms continue, can be severe, and can cause difficulty at school, at home, or with friends. It's not clear what causes the brain differences of ADHD. There’s strong evidence that ADHD is mostly inherited. Many kids who have ADHD have a parent or relative with it. Kids also can be more at risk for it if they were born early, are exposed to environmental toxins, or their mothers used drugs during pregnancy. In adults, the symptoms of ADHD are more difficult to define. This is largely due to a lack of research into adults with ADHD. Treatment for ADHD usually includes: Medicine. This activates the brain's ability to pay attention, slow down, and use more self-control, Behavior therapy. Therapists can help kids develop the social, emotional, and planning skills that are lagging with ADHD, Parent coaching. Through coaching, parents learn the best ways to respond to behavior problems that are part of ADHD.

 

"Attention Deficit Hyperactivity Disorder - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Attention Deficit Hyperactivity Disorder pipeline landscape is provided which includes the disease overview and Attention Deficit Hyperactivity Disorder treatment guidelines. The assessment part of the report embraces, in depth Attention Deficit Hyperactivity Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Attention Deficit Hyperactivity Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Attention Deficit Hyperactivity Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Attention Deficit Hyperactivity Disorder.

Attention Deficit Hyperactivity Disorder Emerging Drugs Chapters

This segment of the Attention Deficit Hyperactivity Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Attention Deficit Hyperactivity Disorder Emerging Drugs

 

Centanafadine: Otsuka Pharmaceutical

Centanafadine is a serotonin-norepinephrine-dopamine, triple-reuptake inhibitor. Approximately, 900 adult patients from age 18 to 55 years old, and diagnosed with ADHD, were randomized in the two phase III studies. The studies were randomized, double-blind, multicenter, and placebo-controlled with parallel groups. Patients were randomized 1:1:1 to receive either centanafadine doses of 100 or 200 mg, twice daily (total daily dose of 200 mg or 400 mg, respectively), or placebo twice daily. In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance. In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine. Centanafadine demonstrated statistically significant improvements vs. placebo for primary and key secondary efficacy endpoints in both investigational studies. In the combined analysis of tolerability across the two studies, no adverse event was reported by more than 7 percent of patients.

 

PDC-142: BioLite, Inc.

PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient. American BriVision receives approval of Taiwan Central Institutional Review Board (CIRB) to initiate a phase II part 2 study in Attention-deficit hyperactivity disorder (ADHD) in Taiwan.

Further product details are provided in the report……..

Attention Deficit Hyperactivity Disorder: Therapeutic Assessment

This segment of the report provides insights about the different Attention Deficit Hyperactivity Disorder drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Attention Deficit Hyperactivity Disorder

There are approx. 20+ key companies which are developing the therapies for Attention Deficit Hyperactivity Disorder. The companies which have their Attention Deficit Hyperactivity Disorder drug candidates in the most advanced stage, i.e. Phase III include, Otsuka Pharmaceutical.

Phases

DelveInsight’s report covers around 22+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Attention Deficit Hyperactivity Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

 

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Attention Deficit Hyperactivity Disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Attention Deficit Hyperactivity Disorder therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Attention Deficit Hyperactivity Disorder drugs.

Attention Deficit Hyperactivity Disorder Report Insights

  • Attention Deficit Hyperactivity Disorder Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Attention Deficit Hyperactivity Disorder Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Attention Deficit Hyperactivity Disorder drugs?
  • How many Attention Deficit Hyperactivity Disorder drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Attention Deficit Hyperactivity Disorder?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Attention Deficit Hyperactivity Disorder therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Attention Deficit Hyperactivity Disorder and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Attention Deficit Hyperactivity Disorder: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

  • Comparative Analysis

Centanafadine: Otsuka Pharmaceutical

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

PDC-142: BioLite, Inc.

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical stage products

  • Comparative Analysis

3Z-20-001: 3Z Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Attention Deficit Hyperactivity Disorder Key Companies

Attention Deficit Hyperactivity Disorder Key Products

Attention Deficit Hyperactivity Disorder- Unmet Needs

Attention Deficit Hyperactivity Disorder- Market Drivers and Barriers

Attention Deficit Hyperactivity Disorder- Future Perspectives and Conclusion

Attention Deficit Hyperactivity Disorder Analyst Views

Attention Deficit Hyperactivity Disorder Key Companies

Appendix

List of Table

Table 1: Total Products for Attention Deficit Hyperactivity Disorder

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type                                              

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Attention Deficit Hyperactivity Disorder

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type                                                                       

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Product

• Materia Medica Holding
• Supernus Pharmaceuticals
• BioLite, Inc.
• Otsuka Pharmaceutical
• EnvisionRx
• KemPharm
• Curemark
• 3Z ehf Pharmaceuticals
• ABVC BioPharma
• AgoneX Biopharmaceuticals
• Arbor Pharmaceuticals
• Cennerv Pharma
• Cingulate
• Ensysce Biosciences
• INVENT Pharmaceuticals
• RespireRx Phamaceuticals
• NLS Pharmaceutics Ltd
• NeuroNascent, Inc.
• Tris Pharma, Inc.

 

Forward to Friend

Need A Quote